Spironolactone-induced agranulocytosis

Agranulocytosis associated with spironolactone administration is described in a 57-year-old man. Four days after initiation of spironolactone, leukocyte counts decreased from 8.2 to 2.3 X 10(9)/L with 6% neutrophils. Spironolactone, domperidone, and prochlorperazine were discontinued. Domperidone an...

Full description

Saved in:
Bibliographic Details
Published inDrug intelligence & clinical pharmacy Vol. 21; no. 12; p. 974
Main Authors Jivraj, K T, Noseworthy, T W, Friesen, E G, Shustack, A S, Konopad, E M, Johnston, R G
Format Journal Article
LanguageEnglish
Published United States 01.12.1987
Subjects
Agranulocytosis - blood
Agranulocytosis - chemically induced
Humans
Leukocyte Count - drug effects
Male
Middle Aged
Spironolactone - adverse effects
Online AccessGet more information

Cover

More Information
Summary:Agranulocytosis associated with spironolactone administration is described in a 57-year-old man. Four days after initiation of spironolactone, leukocyte counts decreased from 8.2 to 2.3 X 10(9)/L with 6% neutrophils. Spironolactone, domperidone, and prochlorperazine were discontinued. Domperidone and prochlorperazine were reintroduced and there was concomitant improvement of the leukocyte and neutrophil counts. Substitution of triamterene for spironolactone was not associated with recurrent leukopenia. The potential association of spironolactone with granulocytopenia warrants increased awareness of this rare but serious adverse drug reaction.
ISSN:0012-6578
DOI:10.1177/106002808702101208